---
figid: PMC7432057__ijms-21-05242-g003
figtitle: Adiponectin and leptin in the progression of nonalcoholic fatty liver disease
  (NAFLD) to hepatocellular carcinoma (HCC)
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Saccharomyces cerevisiae
- Lactobacillus gasseri
organisms_ner:
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Drosophila melanogaster
pmcid: PMC7432057
filename: ijms-21-05242-g003.jpg
figlink: pmc/articles/PMC7432057/figure/ijms-21-05242-f003/
number: F3
caption: Adiponectin and leptin in the progression of nonalcoholic fatty liver disease
  (NAFLD) to hepatocellular carcinoma (HCC). Low adiponectin levels have been observed
  in either NAFLD or nonalcoholic steatohepatitis (NASH) conditions. However, the
  effects on leptin as well as the mechanisms of action of adiponectin are unknown.
  In cirrhosis, circulating adiponectin is elevated. Adiponectin through protein tyrosine
  phosphatase 1B (PTP1B) prevents the leptin-mediated activation of the janus kinase
  2 (Jak2)/signal transducer and activator of transcription-3 (STAT3) pathway through
  suppressors of cytokine signaling 3 (SOCS3) and the activity of focal adhesion kinase
  (FAK) and focal adhesion (FA). By inducing SOCS3, adiponectin suppresses leptin
  activity. Adiponectin can provoke hepatic stellate cells (HSC) apoptosis and leads
  to the loss of α-smooth muscle actin (α-SMA) proteins in HSCs and suppresses HSC
  proliferation and α collagen biosynthesis. Adiponectin-mediated prevention of leptin
  signaling downregulates tissue inhibitor of metalloproteinase 1 (TIMP-1) activity
  and increases matrix metalloproteinase 1 (MMP-1) to degrade fibrillar collagen in
  matrix. Adiponectin increases apoptosis of HCC cells via activation of caspase-3,
  and c-Jun N-terminal kinase (JNK). Adiponectin inhibits leptin-induced proliferation
  of HCC via blockade of STAT-3, protein kinase B (AKT) and mammalian target of rapamycin
  (m-TOR) and shows hepatoprotective functions by blocking angiogenesis and sulfatase
  2.
papertitle: 'Data on Adiponectin from 2010 to 2020: Therapeutic Target and Prognostic
  Factor for Liver Diseases?.'
reftext: Misaq Heydari, et al. Int J Mol Sci. 2020 Aug;21(15):5242.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8940146
figid_alias: PMC7432057__F3
figtype: Figure
redirect_from: /figures/PMC7432057__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7432057__ijms-21-05242-g003.html
  '@type': Dataset
  description: Adiponectin and leptin in the progression of nonalcoholic fatty liver
    disease (NAFLD) to hepatocellular carcinoma (HCC). Low adiponectin levels have
    been observed in either NAFLD or nonalcoholic steatohepatitis (NASH) conditions.
    However, the effects on leptin as well as the mechanisms of action of adiponectin
    are unknown. In cirrhosis, circulating adiponectin is elevated. Adiponectin through
    protein tyrosine phosphatase 1B (PTP1B) prevents the leptin-mediated activation
    of the janus kinase 2 (Jak2)/signal transducer and activator of transcription-3
    (STAT3) pathway through suppressors of cytokine signaling 3 (SOCS3) and the activity
    of focal adhesion kinase (FAK) and focal adhesion (FA). By inducing SOCS3, adiponectin
    suppresses leptin activity. Adiponectin can provoke hepatic stellate cells (HSC)
    apoptosis and leads to the loss of α-smooth muscle actin (α-SMA) proteins in HSCs
    and suppresses HSC proliferation and α collagen biosynthesis. Adiponectin-mediated
    prevention of leptin signaling downregulates tissue inhibitor of metalloproteinase
    1 (TIMP-1) activity and increases matrix metalloproteinase 1 (MMP-1) to degrade
    fibrillar collagen in matrix. Adiponectin increases apoptosis of HCC cells via
    activation of caspase-3, and c-Jun N-terminal kinase (JNK). Adiponectin inhibits
    leptin-induced proliferation of HCC via blockade of STAT-3, protein kinase B (AKT)
    and mammalian target of rapamycin (m-TOR) and shows hepatoprotective functions
    by blocking angiogenesis and sulfatase 2.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HCC
  - HYCC1
  - ARSH
  - JAK2
  - PTPN1
  - STAT3
  - SOCS3
  - AKT1
  - AKT2
  - AKT3
  - RORC
  - MTOR
  - ACTA1
  - COL6A1
  - COL6A2
  - COL6A3
  - COL6A5
  - COL6A6
  - COL7A1
  - COL8A1
  - COL8A2
  - COL9A1
  - COL9A2
  - COL9A3
  - COL10A1
  - COL11A1
  - COL11A2
  - COL12A1
  - COL13A1
  - COL14A1
  - COL15A1
  - COL16A1
  - COL17A1
  - COL18A1
  - COL19A1
  - COL20A1
  - COL21A1
  - COL22A1
  - COL23A1
  - COL24A1
  - COL25A1
  - COL26A1
  - COL27A1
  - COL28A1
  - COL1A1
  - COL1A2
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - COL5A1
  - COL5A2
  - COL5A3
  - TIMP1
  - MMP1
  - FUT1
  - PTK2
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
  - MAPK8
  - MAPK9
  - MAPK10
  - Tsc2
  - Jak2
  - Ptpn1
  - Stat3
  - Socs3
  - Akt1
  - tor
  - Rorc
  - Mtor
  - Acta2
  - Timp1
  - Mmp13
  - Ptk2
  - fa
  - Mapk8
  - Samsn1
  - Mmp1
  - Ptp61F
  - Akt
  - Tor
  - Egfr
  - Timp
  - Hcs
  - Fak
  - bsk
---
